文献速递心力衰竭与心肌病

重新定义慢性心力衰竭患者的铁缺乏

Redefining Iron Deficiency in Patients With Chronic Heart Failure.
PubMed 文献 · Circulation · 2024-05-11

本文指出,基于血清铁蛋白的传统铁缺乏定义在心力衰竭患者中不可靠,可能纳入非铁缺乏且预后良好、对铁治疗无反应者。推荐采用基于低铁血症(TSAT<20%)的定义,该定义与骨髓铁缺乏一致,且静脉铁治疗后改善运动耐量和功能容量,并显著降低心血管死亡或总心衰住院风险20%-30%。

要点

  • 血清铁蛋白阈值受炎症、CKD及心衰影响,不反映绝对或功能性铁缺乏。
  • TSAT<20%的低铁血症患者骨髓铁缺乏,静脉铁治疗可改善症状及预后。
  • 建议放弃铁蛋白驱动的铁缺乏定义,采用TSAT<20%定义心衰铁缺乏。

核心结论

  • 心衰中铁缺乏应基于低铁血症(TSAT<20%)定义,而非血清铁蛋白阈值。

研究设计与样本

  • 本文为综述,回顾历史诊断标准及试验证据,未报告系统检索范围。

主要发现

  • 血清铁蛋白<15-20 μg/L曾用于识别骨髓铁缺乏,但炎症状态可扭曲铁蛋白水平。
  • 约25年前CKD诊断阈值提高5-20倍:铁蛋白<100 μg/L(不论TSAT)或100-299 μg/L且TSAT<20%。
  • 该CKD标准旨在促进铁剂使用以增强促红细胞生成素反应,非基于全身或组织铁耗竭研究。
  • 心衰中该定义不能可靠识别绝对或功能性铁缺乏,且纳入TSAT≥20%、铁蛋白20-100 mg/L的非铁缺乏者。
  • 脑啡肽酶抑制剂和SGLT2抑制剂可能动员内源性铁储备,扭曲铁蛋白水平。

关键数值与推荐

  • 历史铁缺乏诊断:血清铁蛋白<15-20 μg/L。
  • CKD诊断阈值:铁蛋白<100 μg/L(不论TSAT)或100-299 μg/L且TSAT<20%。
  • 推荐心衰铁缺乏定义:TSAT<20%。

临床怎么用

  • 心衰患者应使用TSAT<20%诊断铁缺乏,而非依赖血清铁蛋白阈值。
  • 对TSAT<20%且功能容量受损者,静脉铁治疗可改善运动耐量和功能容量。
  • TSAT≥20%且铁蛋白正常者不推荐基于铁蛋白阈值进行铁治疗。

局限性

  • 本文为综述,未报告系统检索策略及纳入研究细节。
  • 铁蛋白受炎症及药物影响,具体阈值未在文中重新验证。
  • 推荐基于现有试验证据,未提供新原始数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A serum ferritin level <15 to 20 μg/L historically identified patients who had absent bone marrow iron stores, but serum ferritin levels are distorted by the systemic inflammatory states seen in patients with chronic kidney disease or heart failure. As a result, nearly 25 years ago, the diagnostic ferritin threshold was increased 5- to 20-fold in patients with chronic kidney disease (ie, iron deficiency was identified if the serum ferritin level was <100 μg/L, regardless of transferrin saturation [TSAT], or 100 to 299 μg/L if TSAT was <20%). This guidance was motivated not by the findings of studies of total body or tissue iron depletion, but by a desire to encourage the use of iron supplements to potentiate the response to erythropoiesis-stimulating agents in patients with renal anemia. However, in patients with heart failure, this definition does not reliably identify patients with an absolute or functional iron-deficiency state, and it includes individuals with TSATs (≥20%) and serum ferritin levels in the normal range (20-100 mg/L) who are not iron deficient, have an excellent prognosis, and do not respond favorably to iron therapy. Furthermore, serum ferritin levels may be distorted by the use of both neprilysin and sodium-glucose cotransporter 2 inhibitors, both of which may act to mobilize endogenous iron stores. The most evidence-based and trial-tested definition of iron deficiency is the presence of hypoferremia, as reflected by as a TSAT <20%. These hypoferremic patients are generally iron deficient on bone marrow examination, and after intravenous iron therapy, they exhibit an improvement in exercise tolerance and functional capacity (when meaningfully impaired) and show the most marked reduction (ie, 20%-30%) in the risk of cardiovascular death or total heart failure hospitalizations. Therefore, we propose that the current ferritin-driven definition of iron deficiency in heart failure should be abandoned and that a definition based on hypoferremia (TSAT <20%) should be adopted.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Packer, Anker, Butler, et al. Redefining Iron Deficiency in Patients With Chronic Heart Failure. Circulation. 2024. PMID: 38733252. doi:10.1161/CIRCULATIONAHA.124.068883

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。